Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
🎉PAAB Celebrates AstraZeneca’s Industry-Leading Commitment to Innovation
-
Good Morning @Manufacturer @Agency
PAAB is thrilled to announce that AstraZeneca is the first manufacturer to opt into supporting augmentation of the PAAB AI Preclearance Model through use of their de-identified submissions.
We look forward to seeing which manufacturers will join AstraZeneca in seizing this opportunity. Those who opt in before we begin training the first real-life model will be among the first to benefit from this groundbreaking innovation. Don’t miss your chance to be part of this industry-first initiative! Learn more HERE.
